SCHEMBL1686459

SCHEMBL1686459

CCCCCO[Si](O)(O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.44
TSHR P16473 3/20 0.43
CYP3A4 P08684 2/20 0.43
TP53 P04637 2/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.38
NR1I2 O75469 1/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
MAPT P10636 1/20 0.38
OPRK1 P41145 1/20 0.38
HTR2B P41595 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NR5A1 Q13285 1/20 0.38
SOAT1 P35610 1/20 0.38
FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1687034 0.98 TSHR (0.45) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL1686749 0.98 TSHR (0.45) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL1686488 0.98 TSHR (0.45) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL1686936 0.98 TSHR (0.45) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL1686754 0.98 TSHR (0.45) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL1686817 0.94 LTA4H (0.44) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL1686640 0.86 LMNA (0.41) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL19809188 0.85 LTA4H (0.44) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL8048262 0.84 TSHR (0.45) LTA4HTSHRCYP3A4TP53MAPK1
SCHEMBL8034448 0.84 TSHR (0.45) LTA4HTSHRCYP3A4TP53MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932330-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-7592402-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-09-22 US disclosed
US-20080319148-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2008-12-25 US disclosed
US-7115539-B2 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
US-20050245701-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2005-11-03 US disclosed
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer AP1M1, PYM1, SEM1 LTA4H 2243/4885TSHR 4012/4885CYP3A4 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.